According to OG Analysis, the global Companion Diagnostics Oncology Market is estimated at USD 5.11 billion in 2026 and projected to reach USD 12.3 billion by 2034, representing a CAGR of 11.61%. Expanding targeted therapy indications, molecular testing and pharmaceutical partnerships support demand for validated patient-selection assays.
Market Overview
Oncology companion diagnostics measure biomarkers needed to guide the use of specific cancer treatments. Tests identify genomic alterations or protein expression in tumor tissue and, for appropriate validated assays, circulating DNA in blood. Polymerase chain reaction (PCR), next-generation sequencing (NGS) and immunohistochemistry (IHC) serve different testing requirements. Commercial activity spans assay kits, sequencing platforms, laboratory services and interpretation software. Approved clinical use remains specific to the test, biomarker, cancer and therapy described in its labeling.
Key Market Insights
? NGS panels assess multiple alterations within one workflow, while targeted PCR and IHC remain relevant for specific biomarkers.
? Liquid biopsy expands sampling options, although negative plasma findings can require tissue testing under applicable product labeling.
? Drug and diagnostic co-development connects assay validation with clinical trials, regulatory submissions and treatment commercialization.
? Laboratories evaluate specimen requirements, analytical performance, workflow compatibility and reporting alongside the breadth of approved indications.
? Automation can support local NGS implementation, while centralized testing relies on efficient sample transport and clinical reporting.
Market Dynamics
? Additional biomarker-defined treatment indications expand the situations in which validated companion testing is required.
? Multiplex testing can reduce sequential assays, but broader genomic coverage does not make every finding clinically actionable.
? Limited tissue, sample quality and plasma-test sensitivity influence assay selection and laboratory workflows.
? Pharmaceutical partnerships support evidence generation and coordinated development of diagnostic and therapeutic products.
? Coding, payer coverage and reimbursement affect laboratory adoption and commercial access to molecular testing.
? Automated preparation, sequencing and analysis can reduce manual work and support implementation in local laboratories.
? Country-specific authorization requirements and laboratory capacity shape the pace of geographic expansion.
Browse for More Information
https://www.oganalysis.com/industry-reports/companion-diagnostics-oncology-market
Market Segmentation
Published report coverage includes: By Product Type: Biomarkers; Test Kits; Software. By Application: Breast Cancer; Lung Cancer; Colorectal Cancer; Hematologic Malignancies. By End User: Hospitals; Diagnostic Laboratories; Research Institutes. By Technology: PCR; NGS; IHC. By Distribution Channel: Direct Sales; Distributors; E-commerce. Geographic coverage includes North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.
Regional Insights
? North America: The United States has a broad portfolio of authorized tissue- and plasma-based companion diagnostics. Therapy-specific approvals and drug-diagnostic collaboration shape commercialization.
? Europe: IVDR conformity assessment and consultation with the relevant medicines authority affect market access. Manufacturers must align diagnostic evidence and intended use with the associated therapy.
? Asia-Pacific: Japan's published companion diagnostic portfolio illustrates established pathways for therapy-linked assays. Country-specific authorizations remain important for introducing tests across the region.
? The Middle East and Africa: Hikma's agreement with Guardant Health covers genomic profiling commercialization in the Middle East and North Africa, illustrating the role of regional access networks.
? South and Central America: Roche and Foundation Medicine's Brazilian partnership with Grupo Fleury supports sales and sample-export logistics. Genomic analysis remains at Foundation Medicine's Boston laboratory.
Competitive Landscape
Competition includes assay manufacturers, sequencing-platform suppliers and specialist laboratories. Roche combines VENTANA tissue diagnostics with Foundation Medicine's tissue and plasma genomic profiling. Agilent supplies PD-L1 IHC assays, while QIAGEN offers therascreen PCR tests. These portfolios address different biomarkers and laboratory workflows.
Thermo Fisher Scientific's Oncomine Dx assays and Illumina's TruSight Oncology Comprehensive support NGS-based testing. Guardant Health provides blood-based companion diagnostics, while Myriad Genetics offers myChoice CDx for defined oncology applications. Competitive comparisons depend on approved indications and specimen requirements, alongside analytical performance and practical implementation.
Companies expand through pharmaceutical co-development, additional companion indications and improved laboratory workflows. Thermo Fisher's automated Genexus Dx workflow illustrates investment in local testing capabilities. Commercial success also depends on reimbursement, dependable logistics and reporting that distinguishes approved therapy-selection findings from broader genomic profiling results.
Recent Developments
? September 4, 2026: FDA expanded Guardant360 CDx labeling to identify ESR1 mutations in breast cancer patients eligible for ETCAMAH (camizestrant). The linked regimen received accelerated approval for HR-positive, HER2-negative advanced disease after mutation detection during aromatase inhibitor and CDK4/6 inhibitor therapy.
? August 14, 2026: FDA expanded Illumina's TruSight Oncology Comprehensive indication to identify RET fusions in thyroid cancer and RET small DNA variants in medullary thyroid cancer. The companion diagnostic supports selection of eligible patients for RETEVMO (selpercatinib).
? June 10, 2026: FDA expanded Guardant360 CDx indications to detect specified HER2/ERBB2 tyrosine kinase domain activating mutations in non-small cell lung cancer. The blood-based assay identifies patients eligible for HERNEXEOS (zongertinib), extending its therapy-linked liquid biopsy applications.
? May 27, 2026: FDA expanded FoundationOne CDx and FoundationOne Liquid CDx indications to detect specified homologous recombination repair gene alterations in metastatic castration-resistant prostate cancer. The tissue- and plasma-based tests support selection for TALZENNA (talazoparib) combined with XTANDI (enzalutamide).
? March 10, 2026: FDA changed MyChoice CDx labeling from complementary to companion diagnostic status for ZEJULA (niraparib). The assay identifies eligible ovarian cancer patients using deleterious or suspected deleterious BRCA1/2 alterations and/or a positive genomic instability score.
Comments